izpis_h1_title_alt

Rational design of balanced dual-targeting antibiotics with limited resistance
ID Nyerges, Ákos (Author), ID Tomašič, Tihomir (Author), ID Durcik, Martina (Author), ID Revesz, T. (Author), ID Szili, Petra (Author), ID Skok, Žiga (Author), ID Zidar, Nace (Author), ID Ilaš, Janez (Author), ID Zega, Anamarija (Author), ID Kikelj, Danijel (Author), ID Peterlin-Mašič, Lucija (Author)

.pdfPDF - Presentation file, Download (2,33 MB)
MD5: 8635951289FE951C6B89CB716C918D0C
URLURL - Source URL, Visit https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000819 This link opens in a new window

Abstract
Antibiotics that inhibit multiple bacterial targets offer a promising therapeutic strategy against resistance evolution, but developing such antibiotics is challenging. Here we demonstrate that a rational design of balanced multitargeting antibiotics is feasible by using a medicinal chemistry workflow. The resultant lead compounds, ULD1 and ULD2, belonging to a novel chemical class, almost equipotently inhibit bacterial DNA gyrase and topoisomerase IV complexes and interact with multiple evolutionary conserved amino acids in the ATP-binding pockets of their target proteins. ULD1 and ULD2 are excellently potent against a broad range of gram-positive bacteria. Notably, the efficacy of these compounds was tested against a broad panel of multidrug-resistant Staphylococcus aureus clinical strains. Antibiotics with clinical relevance against staphylococcal infections fail to inhibit a significant fraction of these isolates, whereas both ULD1 and ULD2 inhibit all of them (minimum inhibitory concentration [MIC] +-1 [micro]g/mL). Resistance mutations against these compounds are rare, have limited impact on compound susceptibility, and substantially reduce bacterial growth. Based on their efficacy and lack of toxicity demonstrated in murine infection models, these compounds could translate into new therapies against multidrug-resistant bacterial infections.

Language:English
Keywords:antibiotics, bacterial resistance, bacterial targets
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:Str. 1-31
Numbering:Vol. 18, iss. 10
PID:20.500.12556/RUL-141942 This link opens in a new window
UDC:615.4:54:615.33
ISSN on article:1545-7885
DOI:10.1371/journal.pbio.3000819 This link opens in a new window
COBISS.SI-ID:31342595 This link opens in a new window
Publication date in RUL:12.10.2022
Views:608
Downloads:70
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:PLoS biology
Shortened title:PLoS biol.
Publisher:PLOS
ISSN:1545-7885
COBISS.SI-ID:2943764 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:antibiotiki, farmacevtska kemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208-2015
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J1-9192-2018
Name:Nove protitumorne učinovine napetostno odvisnih kalijevih kanalov hEag1 in njihova validacija v limfomih

Funder:EC - European Commission
Funding programme:European Commission
Project number:739593
Name:Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership with EMBL
Acronym:HCEMM

Funder:Other - Other funder or multiple funders
Funding programme:European Research Council
Project number:H2020-ERC-2014-CoG 648364
Name:Resistance Evolution

Funder:Other - Other funder or multiple funders
Funding programme:Ce´lzott Lendu¨let’ Programme of the Hungarian Academy of Sciences
Project number:LP-2017–10/2017

Funder:Other - Other funder or multiple funders
Funding programme:‘E´lvonal’ KKP
Project number:126506

Funder:Other - Other funder or multiple funders
Funding programme:GINOP
Project number:2.3.2–15– 2016–00014
Name:EVOMER

Funder:Other - Other funder or multiple funders
Funding programme:GINOP
Project number:2.3.2–15– 2016–00020
Name:MolMedEx TUMORDNS

Funder:Other - Other funder or multiple funders
Funding programme:GINOP
Project number:2.3.3–15–2016–00001

Funder:Other - Other funder or multiple funders
Funding programme:EFOP
Project number:d3.6.3-VEKOP-16-2017-00009

Funder:Other - Other funder or multiple funders
Funding programme:UNKP
Project number:19-3
Name:New National Excellence Program of the Ministry for Innovation and Technology

Funder:Other - Other funder or multiple funders
Funding programme:PhD fellowship from the Boehringer Ingelheim Fonds

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back